Lejla Delic, MD
Gynecologic Oncology · San Francisco, CANPI 1063615185
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,675 of the $15,827 with a category attached, or 61.1%. Myriad Genetic Laboratories, Inc. accounts for 77.1% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $6,476 and has fallen 56.9% since, to $2,793 in 2025.
Across 60 payments — averaging $263.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myriad Genetic Laboratories, Inc.$12K
- AbbVie$2K
- Intuitive Surgical$289
- GSK$228
- AstraZeneca$196
- Bard Peripheral Vascular, Inc.$166
- plus $273 from 3 others
What the payments were for
- Consulting fees$1,90012%
- Speaking & faculty fees$9,67561%
- Travel & lodging$1,98613%
- Food & beverage$2,25314%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myriad Genetic Laboratories, Inc. | 41 | $12,205 |
| AbbVie | 6 | $2,472 |
| Intuitive Surgical | 4 | $289 |
| GSK | 2 | $228 |
| AstraZeneca | 2 | $196 |
| Bard Peripheral Vascular, Inc. | 2 | $166 |
| Seagen Inc. | 1 | $136 |
| Eisai Inc. | 1 | $124 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- myChoice CDx$6,365
- myRisk$3,058
- Elahere$2,350
- BRAC CDx$1,200
- PreciseTumor$792
- Da Vinci Surgical System$256
- ZEJULA$228
- RiskScore$150
- TIVDAK$136
- LYNPARZA$125
- LENVIMA$124
How this compares
$15,827 in reported general payments places this provider in the 80th percentile of 152 gynecologic oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 15 | $1,023 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in San Francisco
- John ChanSan Francisco$2M
- Katherine FuhSan Francisco$26K
- Dana ChaseLos Angeles$1.3M
- Ramez EskanderEncinitas$706K
- Krishnansu TewariOrange$495K
- Fabio CappucciniOrange$313K
- Mehdi Moslemi-KebriaUpland$225K
- Amer KaramStanford$168K
- Rebecca BrooksSacramento$133K
- Kenneth KimWest Hollywood$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.